Neuroimmune Therapy Market Forecasts to 2034 – Global Analysis By Therapy Type (Monoclonal Antibodies, Immunomodulators, Cytokine Inhibitors, Cell-Based Therapies, Gene Therapies, Small Molecule Drugs, and Combination Therapies), Indication, Route of Administration, Technology, End User, Distribution Channel, and By Geography
According to Stratistics MRC, the Global Neuroimmune Therapy Market is accounted for $28.2 billion in 2026 and is expected to reach $63.3 billion by 2034 growing at a CAGR of 10.6% during the forecast period. Neuroimmune therapy refers to medical treatments that target the intersection of the nervous system and immune system to address neurological diseases driven or worsened by abnormal immune activity. These therapies include monoclonal antibodies, immunomodulators, cytokine inhibitors, cell-based treatments, and gene therapies designed to regulate neuroinflammation and restore immune balance in conditions such as multiple sclerosis, autoimmune encephalitis, and neurodegenerative diseases. By precisely modulating immune pathways in the brain and nervous system, neuroimmune therapies offer new hope for patients with previously untreatable or poorly managed neurological conditions.
Market Dynamics:
Driver:
Rising prevalence of autoimmune neurological diseases
The global burden of neuroimmune diseases, including multiple sclerosis, neuromyelitis optica, autoimmune encephalitis, and neuroinflammatory forms of Alzheimer's disease, is growing as populations age and diagnostic capabilities improve. Advances in understanding the immunological mechanisms underlying neurological damage have opened new therapeutic windows that targeted biologics, immunomodulators, and cell-based therapies can exploit. The combination of growing patient populations, significant unmet medical need, and rapidly maturing neuroimmunology science is driving substantial pharmaceutical investment in developing and commercializing.
Restraint:
High drug development and clinical trial costs
Developing novel neuroimmune therapies, particularly biologic agents such as monoclonal antibodies and cell-based therapies targeting the central nervous system, requires enormous upfront investment in target validation, preclinical studies, multi-phase clinical trials, and manufacturing infrastructure development. The complexity of demonstrating safety and efficacy in neurological indications, where outcomes are difficult to measure objectively and clinical trial designs are complex, further inflates development costs and timelines. High failure rates in neurology drug development create substantial financial risk.
Opportunity:
Growing pipeline of biologic neurotherapy candidates
The neuroimmune therapy pipeline is among the most active and innovative segments of the broader biopharmaceutical industry, with numerous novel therapeutic candidates in advanced clinical development targeting multiple sclerosis, Alzheimer's neuroinflammation, and rare autoimmune neurological disorders. Advances in antibody engineering, CAR-T cell technology, antisense oligonucleotides, and gene therapy platforms are expanding the range of neuroimmune targets that can be addressed therapeutically. This rich pipeline represents a substantial commercial opportunity as successful candidates advance toward regulatory.
Threat:
Complex regulatory approval for novel biologics
The regulatory pathway for novel biologic therapies targeting the central nervous system is among the most demanding and unpredictable in pharmaceutical development. Regulatory agencies require extensive clinical evidence of safety and efficacy in neurological indications, often including large and long-duration trials with complex outcome measures. Manufacturing biologics to quality and consistency standards required for regulatory approval adds further complexity and cost.
Covid-19 Impact:
The Covid-19 pandemic significantly influenced the Neuroimmune Therapy Market, as the virus highlighted the critical role of immune and neurological interactions in health outcomes. Increased research into post-Covid neurological complications and immune dysregulation accelerated interest in neuroimmune therapies. Pharmaceutical companies and research institutions invested heavily in developing treatments targeting inflammation and immune-related neurological disorders. While clinical trials faced delays due to restrictions, the long-term impact was positive, with heightened awareness driving innovation and positioning neuroimmune therapies as vital in modern healthcare.
The monoclonal antibodies segment is expected to be the largest during the forecast period
The monoclonal antibodies segment holds the largest share in the neuroimmune therapy market. These highly specific biologics have transformed treatment for multiple sclerosis, neuromyelitis optica, and other autoimmune neurological conditions by selectively targeting pathological immune pathways. Their proven clinical efficacy, established manufacturing processes, and growing number of approved products create a large and commercially dominant segment. Continued clinical trials exploring new neuroimmune indications further expand the addressable market for monoclonal antibody therapies.
The multiple sclerosis segment is expected to have the highest CAGR during the forecast period
The multiple sclerosis segment is expected to register the highest CAGR in the neuroimmune therapy market over the forecast period. MS remains the most prevalent serious neuroimmune disease globally, with a growing diagnosed patient population and strong unmet medical need for more effective therapies. Rapid development of next-generation disease-modifying therapies, expanding biological treatment options, and increasing investment in precision neuroimmune medicine for MS patients are driving the segment's exceptional compound annual growth rate across the forecast period.
Region with largest share:
During the forecast period, the North America region is expected to hold the largest market share owing to its advanced healthcare infrastructure, strong presence of pharmaceutical companies, and robust investment in neuroimmune research. The region benefits from supportive government initiatives, high prevalence of autoimmune and neurological disorders, and collaborations between biotech firms and academic institutions. Additionally, early adoption of innovative therapies and strong regulatory frameworks ensure North America remains the leading hub for neuroimmune therapy development and commercialization.
Region with highest CAGR:
Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, due to rising healthcare expenditure, growing awareness of neurological and immune-related conditions, and expanding pharmaceutical research capabilities. Countries such as China, India, and Japan are investing heavily in biotechnology and advanced therapies, supported by government initiatives promoting healthcare innovation. Increasing prevalence of neuroimmune disorders, coupled with a large patient population, drives demand. With rapid technological adoption and supportive policies, Asia Pacific emerges as the fastest-growing region in this market.
Key players in the market
Some of the key players in Neuroimmune Therapy Market include Roche Holding AG, Novartis AG, Pfizer Inc., Johnson & Johnson, Bristol-Myers Squibb Company, Biogen Inc., Merck & Co., Inc., Eli Lilly and Company, Sanofi S.A., AbbVie Inc., GlaxoSmithKline plc, Amgen Inc., UCB S.A., Takeda Pharmaceutical Company Limited, AstraZeneca plc, Regeneron Pharmaceuticals, Inc., Bayer AG, and Teva Pharmaceutical Industries Ltd.
Key Developments:
In February 2026, Pfizer emphasized AI-enabled neuroimmune therapy platforms, projecting improved treatment efficiency and patient monitoring. At global medical summits, the company showcased demand response automation for neurological care, highlighting sustainability, personalization, and resilience in addressing complex immune-related health challenges.
In January 2026, Roche advanced neuroimmune therapy research, unveiling AI-driven analytics for personalized treatment pathways. The company emphasized demand-responsive clinical solutions, integrating predictive models to optimize resilience, efficiency, and patient outcomes across neurological and autoimmune conditions worldwide.
In January 2026, Novartis introduced innovative neuroimmune therapies, leveraging digital twins and machine learning for adaptive treatment. The initiative focused on demand-responsive drug development, enhancing sustainability, efficiency, and resilience while supporting flexible deployment across hospitals, clinics, and global healthcare ecosystems.
Therapy Types Covered:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
Market Dynamics:
Driver:
Rising prevalence of autoimmune neurological diseases
The global burden of neuroimmune diseases, including multiple sclerosis, neuromyelitis optica, autoimmune encephalitis, and neuroinflammatory forms of Alzheimer's disease, is growing as populations age and diagnostic capabilities improve. Advances in understanding the immunological mechanisms underlying neurological damage have opened new therapeutic windows that targeted biologics, immunomodulators, and cell-based therapies can exploit. The combination of growing patient populations, significant unmet medical need, and rapidly maturing neuroimmunology science is driving substantial pharmaceutical investment in developing and commercializing.
Restraint:
High drug development and clinical trial costs
Developing novel neuroimmune therapies, particularly biologic agents such as monoclonal antibodies and cell-based therapies targeting the central nervous system, requires enormous upfront investment in target validation, preclinical studies, multi-phase clinical trials, and manufacturing infrastructure development. The complexity of demonstrating safety and efficacy in neurological indications, where outcomes are difficult to measure objectively and clinical trial designs are complex, further inflates development costs and timelines. High failure rates in neurology drug development create substantial financial risk.
Opportunity:
Growing pipeline of biologic neurotherapy candidates
The neuroimmune therapy pipeline is among the most active and innovative segments of the broader biopharmaceutical industry, with numerous novel therapeutic candidates in advanced clinical development targeting multiple sclerosis, Alzheimer's neuroinflammation, and rare autoimmune neurological disorders. Advances in antibody engineering, CAR-T cell technology, antisense oligonucleotides, and gene therapy platforms are expanding the range of neuroimmune targets that can be addressed therapeutically. This rich pipeline represents a substantial commercial opportunity as successful candidates advance toward regulatory.
Threat:
Complex regulatory approval for novel biologics
The regulatory pathway for novel biologic therapies targeting the central nervous system is among the most demanding and unpredictable in pharmaceutical development. Regulatory agencies require extensive clinical evidence of safety and efficacy in neurological indications, often including large and long-duration trials with complex outcome measures. Manufacturing biologics to quality and consistency standards required for regulatory approval adds further complexity and cost.
Covid-19 Impact:
The Covid-19 pandemic significantly influenced the Neuroimmune Therapy Market, as the virus highlighted the critical role of immune and neurological interactions in health outcomes. Increased research into post-Covid neurological complications and immune dysregulation accelerated interest in neuroimmune therapies. Pharmaceutical companies and research institutions invested heavily in developing treatments targeting inflammation and immune-related neurological disorders. While clinical trials faced delays due to restrictions, the long-term impact was positive, with heightened awareness driving innovation and positioning neuroimmune therapies as vital in modern healthcare.
The monoclonal antibodies segment is expected to be the largest during the forecast period
The monoclonal antibodies segment holds the largest share in the neuroimmune therapy market. These highly specific biologics have transformed treatment for multiple sclerosis, neuromyelitis optica, and other autoimmune neurological conditions by selectively targeting pathological immune pathways. Their proven clinical efficacy, established manufacturing processes, and growing number of approved products create a large and commercially dominant segment. Continued clinical trials exploring new neuroimmune indications further expand the addressable market for monoclonal antibody therapies.
The multiple sclerosis segment is expected to have the highest CAGR during the forecast period
The multiple sclerosis segment is expected to register the highest CAGR in the neuroimmune therapy market over the forecast period. MS remains the most prevalent serious neuroimmune disease globally, with a growing diagnosed patient population and strong unmet medical need for more effective therapies. Rapid development of next-generation disease-modifying therapies, expanding biological treatment options, and increasing investment in precision neuroimmune medicine for MS patients are driving the segment's exceptional compound annual growth rate across the forecast period.
Region with largest share:
During the forecast period, the North America region is expected to hold the largest market share owing to its advanced healthcare infrastructure, strong presence of pharmaceutical companies, and robust investment in neuroimmune research. The region benefits from supportive government initiatives, high prevalence of autoimmune and neurological disorders, and collaborations between biotech firms and academic institutions. Additionally, early adoption of innovative therapies and strong regulatory frameworks ensure North America remains the leading hub for neuroimmune therapy development and commercialization.
Region with highest CAGR:
Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, due to rising healthcare expenditure, growing awareness of neurological and immune-related conditions, and expanding pharmaceutical research capabilities. Countries such as China, India, and Japan are investing heavily in biotechnology and advanced therapies, supported by government initiatives promoting healthcare innovation. Increasing prevalence of neuroimmune disorders, coupled with a large patient population, drives demand. With rapid technological adoption and supportive policies, Asia Pacific emerges as the fastest-growing region in this market.
Key players in the market
Some of the key players in Neuroimmune Therapy Market include Roche Holding AG, Novartis AG, Pfizer Inc., Johnson & Johnson, Bristol-Myers Squibb Company, Biogen Inc., Merck & Co., Inc., Eli Lilly and Company, Sanofi S.A., AbbVie Inc., GlaxoSmithKline plc, Amgen Inc., UCB S.A., Takeda Pharmaceutical Company Limited, AstraZeneca plc, Regeneron Pharmaceuticals, Inc., Bayer AG, and Teva Pharmaceutical Industries Ltd.
Key Developments:
In February 2026, Pfizer emphasized AI-enabled neuroimmune therapy platforms, projecting improved treatment efficiency and patient monitoring. At global medical summits, the company showcased demand response automation for neurological care, highlighting sustainability, personalization, and resilience in addressing complex immune-related health challenges.
In January 2026, Roche advanced neuroimmune therapy research, unveiling AI-driven analytics for personalized treatment pathways. The company emphasized demand-responsive clinical solutions, integrating predictive models to optimize resilience, efficiency, and patient outcomes across neurological and autoimmune conditions worldwide.
In January 2026, Novartis introduced innovative neuroimmune therapies, leveraging digital twins and machine learning for adaptive treatment. The initiative focused on demand-responsive drug development, enhancing sustainability, efficiency, and resilience while supporting flexible deployment across hospitals, clinics, and global healthcare ecosystems.
Therapy Types Covered:
- Monoclonal Antibodies
- Immunomodulators
- Cytokine Inhibitors
- Cell-Based Therapies
- Gene Therapies
- Small Molecule Drugs
- Combination Therapies
- Multiple Sclerosis
- Neuromyelitis Optica
- Autoimmune Encephalitis
- Myasthenia Gravis
- Alzheimer’s Disease
- Parkinson’s Disease
- Intravenous
- Subcutaneous
- Oral
- Intratheca
- Biologics Development
- Recombinant DNA Technology
- Cell Engineering
- Precision Medicine Platforms
- Hospitals
- Specialty Clinics
- Research Institutes
- Ambulatory Surgical Centers
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- North America
- United States
- Canada
- Mexico
- Europe
- United Kingdom
- Germany
- France
- Italy
- Spain
- Netherlands
- Belgium
- Sweden
- Switzerland
- Poland
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Vietnam
- Rest of Asia Pacific
- South America
- Brazil
- Argentina
- Colombia
- Chile
- Peru
- Rest of South America
- Rest of the World (RoW)
- Middle East
- Saudi Arabia
- United Arab Emirates
- Qatar
- Israel
- Rest of Middle East
- Africa
- South Africa
- Egypt
- Morocco
- Rest of Africa
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
- Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
- Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
- Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
1 EXECUTIVE SUMMARY
1.1 Market Snapshot and Key Highlights
1.2 Growth Drivers, Challenges, and Opportunities
1.3 Competitive Landscape Overview
1.4 Strategic Insights and Recommendations
2 RESEARCH FRAMEWORK
2.1 Study Objectives and Scope
2.2 Stakeholder Analysis
2.3 Research Assumptions and Limitations
2.4 Research Methodology
2.4.1 Data Collection (Primary and Secondary)
2.4.2 Data Modeling and Estimation Techniques
2.4.3 Data Validation and Triangulation
2.4.4 Analytical and Forecasting Approach
3 MARKET DYNAMICS AND TREND ANALYSIS
3.1 Market Definition and Structure
3.2 Key Market Drivers
3.3 Market Restraints and Challenges
3.4 Growth Opportunities and Investment Hotspots
3.5 Industry Threats and Risk Assessment
3.6 Technology and Innovation Landscape
3.7 Emerging and High-Growth Markets
3.8 Regulatory and Policy Environment
3.9 Impact of COVID-19 and Recovery Outlook
4 COMPETITIVE AND STRATEGIC ASSESSMENT
4.1 Porter's Five Forces Analysis
4.1.1 Supplier Bargaining Power
4.1.2 Buyer Bargaining Power
4.1.3 Threat of Substitutes
4.1.4 Threat of New Entrants
4.1.5 Competitive Rivalry
4.2 Market Share Analysis of Key Players
4.3 Product Benchmarking and Performance Comparison
5 GLOBAL NEUROIMMUNE THERAPY MARKET, BY THERAPY TYPE
5.1 Monoclonal Antibodies
5.2 Immunomodulators
5.3 Cytokine Inhibitors
5.4 Cell-Based Therapies
5.5 Gene Therapies
5.6 Small Molecule Drugs
5.7 Combination Therapies
6 GLOBAL NEUROIMMUNE THERAPY MARKET, BY INDICATION
6.1 Multiple Sclerosis
6.2 Neuromyelitis Optica
6.3 Autoimmune Encephalitis
6.4 Myasthenia Gravis
6.5 Alzheimer’s Disease
6.6 Parkinson’s Disease
7 GLOBAL NEUROIMMUNE THERAPY MARKET, BY ROUTE OF ADMINISTRATION
7.1 Intravenous
7.2 Subcutaneous
7.3 Oral
7.4 Intrathecal
8 GLOBAL NEUROIMMUNE THERAPY MARKET, BY TECHNOLOGY
8.1 Biologics Development
8.2 Recombinant DNA Technology
8.3 Cell Engineering
8.4 Precision Medicine Platforms
9 GLOBAL NEUROIMMUNE THERAPY MARKET, BY END USER
9.1 Hospitals
9.2 Specialty Clinics
9.3 Research Institutes
9.4 Ambulatory Surgical Centers
10 GLOBAL NEUROIMMUNE THERAPY MARKET, BY DISTRIBUTION CHANNEL
10.1 Hospital Pharmacies
10.2 Retail Pharmacies
10.3 Online Pharmacies
11 GLOBAL NEUROIMMUNE THERAPY MARKET, BY GEOGRAPHY
11.1 North America
11.1.1 United States
11.1.2 Canada
11.1.3 Mexico
11.2 Europe
11.2.1 United Kingdom
11.2.2 Germany
11.2.3 France
11.2.4 Italy
11.2.5 Spain
11.2.6 Netherlands
11.2.7 Belgium
11.2.8 Sweden
11.2.9 Switzerland
11.2.10 Poland
11.2.11 Rest of Europe
11.3 Asia Pacific
11.3.1 China
11.3.2 Japan
11.3.3 India
11.3.4 South Korea
11.3.5 Australia
11.3.6 Indonesia
11.3.7 Thailand
11.3.8 Malaysia
11.3.9 Singapore
11.3.10 Vietnam
11.3.11 Rest of Asia Pacific
11.4 South America
11.4.1 Brazil
11.4.2 Argentina
11.4.3 Colombia
11.4.4 Chile
11.4.5 Peru
11.4.6 Rest of South America
11.5 Rest of the World (RoW)
11.5.1 Middle East
11.5.1.1 Saudi Arabia
11.5.1.2 United Arab Emirates
11.5.1.3 Qatar
11.5.1.4 Israel
11.5.1.5 Rest of Middle East
11.5.2 Africa
11.5.2.1 South Africa
11.5.2.2 Egypt
11.5.2.3 Morocco
11.5.2.4 Rest of Africa
12 STRATEGIC MARKET INTELLIGENCE
12.1 Industry Value Network and Supply Chain Assessment
12.2 White-Space and Opportunity Mapping
12.3 Product Evolution and Market Life Cycle Analysis
12.4 Channel, Distributor, and Go-to-Market Assessment
13 INDUSTRY DEVELOPMENTS AND STRATEGIC INITIATIVES
13.1 Mergers and Acquisitions
13.2 Partnerships, Alliances, and Joint Ventures
13.3 New Product Launches and Certifications
13.4 Capacity Expansion and Investments
13.5 Other Strategic Initiatives
14 COMPANY PROFILES
14.1 Roche Holding AG
14.2 Novartis AG
14.3 Pfizer Inc.
14.4 Johnson & Johnson
14.5 Bristol-Myers Squibb Company
14.6 Biogen Inc.
14.7 Merck & Co., Inc.
14.8 Eli Lilly and Company
14.9 Sanofi S.A.
14.10 AbbVie Inc.
14.11 GlaxoSmithKline plc
14.12 Amgen Inc.
14.13 UCB S.A.
14.14 Takeda Pharmaceutical Company Limited
14.15 AstraZeneca plc
14.16 Regeneron Pharmaceuticals, Inc.
14.17 Bayer AG
14.18 Teva Pharmaceutical Industries Ltd.
1.1 Market Snapshot and Key Highlights
1.2 Growth Drivers, Challenges, and Opportunities
1.3 Competitive Landscape Overview
1.4 Strategic Insights and Recommendations
2 RESEARCH FRAMEWORK
2.1 Study Objectives and Scope
2.2 Stakeholder Analysis
2.3 Research Assumptions and Limitations
2.4 Research Methodology
2.4.1 Data Collection (Primary and Secondary)
2.4.2 Data Modeling and Estimation Techniques
2.4.3 Data Validation and Triangulation
2.4.4 Analytical and Forecasting Approach
3 MARKET DYNAMICS AND TREND ANALYSIS
3.1 Market Definition and Structure
3.2 Key Market Drivers
3.3 Market Restraints and Challenges
3.4 Growth Opportunities and Investment Hotspots
3.5 Industry Threats and Risk Assessment
3.6 Technology and Innovation Landscape
3.7 Emerging and High-Growth Markets
3.8 Regulatory and Policy Environment
3.9 Impact of COVID-19 and Recovery Outlook
4 COMPETITIVE AND STRATEGIC ASSESSMENT
4.1 Porter's Five Forces Analysis
4.1.1 Supplier Bargaining Power
4.1.2 Buyer Bargaining Power
4.1.3 Threat of Substitutes
4.1.4 Threat of New Entrants
4.1.5 Competitive Rivalry
4.2 Market Share Analysis of Key Players
4.3 Product Benchmarking and Performance Comparison
5 GLOBAL NEUROIMMUNE THERAPY MARKET, BY THERAPY TYPE
5.1 Monoclonal Antibodies
5.2 Immunomodulators
5.3 Cytokine Inhibitors
5.4 Cell-Based Therapies
5.5 Gene Therapies
5.6 Small Molecule Drugs
5.7 Combination Therapies
6 GLOBAL NEUROIMMUNE THERAPY MARKET, BY INDICATION
6.1 Multiple Sclerosis
6.2 Neuromyelitis Optica
6.3 Autoimmune Encephalitis
6.4 Myasthenia Gravis
6.5 Alzheimer’s Disease
6.6 Parkinson’s Disease
7 GLOBAL NEUROIMMUNE THERAPY MARKET, BY ROUTE OF ADMINISTRATION
7.1 Intravenous
7.2 Subcutaneous
7.3 Oral
7.4 Intrathecal
8 GLOBAL NEUROIMMUNE THERAPY MARKET, BY TECHNOLOGY
8.1 Biologics Development
8.2 Recombinant DNA Technology
8.3 Cell Engineering
8.4 Precision Medicine Platforms
9 GLOBAL NEUROIMMUNE THERAPY MARKET, BY END USER
9.1 Hospitals
9.2 Specialty Clinics
9.3 Research Institutes
9.4 Ambulatory Surgical Centers
10 GLOBAL NEUROIMMUNE THERAPY MARKET, BY DISTRIBUTION CHANNEL
10.1 Hospital Pharmacies
10.2 Retail Pharmacies
10.3 Online Pharmacies
11 GLOBAL NEUROIMMUNE THERAPY MARKET, BY GEOGRAPHY
11.1 North America
11.1.1 United States
11.1.2 Canada
11.1.3 Mexico
11.2 Europe
11.2.1 United Kingdom
11.2.2 Germany
11.2.3 France
11.2.4 Italy
11.2.5 Spain
11.2.6 Netherlands
11.2.7 Belgium
11.2.8 Sweden
11.2.9 Switzerland
11.2.10 Poland
11.2.11 Rest of Europe
11.3 Asia Pacific
11.3.1 China
11.3.2 Japan
11.3.3 India
11.3.4 South Korea
11.3.5 Australia
11.3.6 Indonesia
11.3.7 Thailand
11.3.8 Malaysia
11.3.9 Singapore
11.3.10 Vietnam
11.3.11 Rest of Asia Pacific
11.4 South America
11.4.1 Brazil
11.4.2 Argentina
11.4.3 Colombia
11.4.4 Chile
11.4.5 Peru
11.4.6 Rest of South America
11.5 Rest of the World (RoW)
11.5.1 Middle East
11.5.1.1 Saudi Arabia
11.5.1.2 United Arab Emirates
11.5.1.3 Qatar
11.5.1.4 Israel
11.5.1.5 Rest of Middle East
11.5.2 Africa
11.5.2.1 South Africa
11.5.2.2 Egypt
11.5.2.3 Morocco
11.5.2.4 Rest of Africa
12 STRATEGIC MARKET INTELLIGENCE
12.1 Industry Value Network and Supply Chain Assessment
12.2 White-Space and Opportunity Mapping
12.3 Product Evolution and Market Life Cycle Analysis
12.4 Channel, Distributor, and Go-to-Market Assessment
13 INDUSTRY DEVELOPMENTS AND STRATEGIC INITIATIVES
13.1 Mergers and Acquisitions
13.2 Partnerships, Alliances, and Joint Ventures
13.3 New Product Launches and Certifications
13.4 Capacity Expansion and Investments
13.5 Other Strategic Initiatives
14 COMPANY PROFILES
14.1 Roche Holding AG
14.2 Novartis AG
14.3 Pfizer Inc.
14.4 Johnson & Johnson
14.5 Bristol-Myers Squibb Company
14.6 Biogen Inc.
14.7 Merck & Co., Inc.
14.8 Eli Lilly and Company
14.9 Sanofi S.A.
14.10 AbbVie Inc.
14.11 GlaxoSmithKline plc
14.12 Amgen Inc.
14.13 UCB S.A.
14.14 Takeda Pharmaceutical Company Limited
14.15 AstraZeneca plc
14.16 Regeneron Pharmaceuticals, Inc.
14.17 Bayer AG
14.18 Teva Pharmaceutical Industries Ltd.
LIST OF TABLES
Table 1 Global Neuroimmune Therapy Market Outlook, By Region (2023-2034) ($MN)
Table 2 Global Neuroimmune Therapy Market Outlook, By Therapy Type (2023-2034) ($MN)
Table 3 Global Neuroimmune Therapy Market Outlook, By Monoclonal Antibodies (2023-2034) ($MN)
Table 4 Global Neuroimmune Therapy Market Outlook, By Immunomodulators (2023-2034) ($MN)
Table 5 Global Neuroimmune Therapy Market Outlook, By Cytokine Inhibitors (2023-2034) ($MN)
Table 6 Global Neuroimmune Therapy Market Outlook, By Cell-Based Therapies (2023-2034) ($MN)
Table 7 Global Neuroimmune Therapy Market Outlook, By Gene Therapies (2023-2034) ($MN)
Table 8 Global Neuroimmune Therapy Market Outlook, By Small Molecule Drugs (2023-2034) ($MN)
Table 9 Global Neuroimmune Therapy Market Outlook, By Combination Therapies (2023-2034) ($MN)
Table 10 Global Neuroimmune Therapy Market Outlook, By Indication (2023-2034) ($MN)
Table 11 Global Neuroimmune Therapy Market Outlook, By Multiple Sclerosis (2023-2034) ($MN)
Table 12 Global Neuroimmune Therapy Market Outlook, By Neuromyelitis Optica (2023-2034) ($MN)
Table 13 Global Neuroimmune Therapy Market Outlook, By Autoimmune Encephalitis (2023-2034) ($MN)
Table 14 Global Neuroimmune Therapy Market Outlook, By Myasthenia Gravis (2023-2034) ($MN)
Table 15 Global Neuroimmune Therapy Market Outlook, By Alzheimer’s Disease (2023-2034) ($MN)
Table 16 Global Neuroimmune Therapy Market Outlook, By Parkinson’s Disease (2023-2034) ($MN)
Table 17 Global Neuroimmune Therapy Market Outlook, By Route of Administration (2023-2034) ($MN)
Table 18 Global Neuroimmune Therapy Market Outlook, By Intravenous (2023-2034) ($MN)
Table 19 Global Neuroimmune Therapy Market Outlook, By Subcutaneous (2023-2034) ($MN)
Table 20 Global Neuroimmune Therapy Market Outlook, By Oral (2023-2034) ($MN)
Table 21 Global Neuroimmune Therapy Market Outlook, By Intrathecal (2023-2034) ($MN)
Table 22 Global Neuroimmune Therapy Market Outlook, By Technology (2023-2034) ($MN)
Table 23 Global Neuroimmune Therapy Market Outlook, By Biologics Development (2023-2034) ($MN)
Table 24 Global Neuroimmune Therapy Market Outlook, By Recombinant DNA Technology (2023-2034) ($MN)
Table 25 Global Neuroimmune Therapy Market Outlook, By Cell Engineering (2023-2034) ($MN)
Table 26 Global Neuroimmune Therapy Market Outlook, By Precision Medicine Platforms (2023-2034) ($MN)
Table 27 Global Neuroimmune Therapy Market Outlook, By End User (2023-2034) ($MN)
Table 28 Global Neuroimmune Therapy Market Outlook, By Hospitals (2023-2034) ($MN)
Table 29 Global Neuroimmune Therapy Market Outlook, By Specialty Clinics (2023-2034) ($MN)
Table 30 Global Neuroimmune Therapy Market Outlook, By Research Institutes (2023-2034) ($MN)
Table 31 Global Neuroimmune Therapy Market Outlook, By Ambulatory Surgical Centers (2023-2034) ($MN)
Table 32 Global Neuroimmune Therapy Market Outlook, By Distribution Channel (2023-2034) ($MN)
Table 33 Global Neuroimmune Therapy Market Outlook, By Hospital Pharmacies (2023-2034) ($MN)
Table 34 Global Neuroimmune Therapy Market Outlook, By Retail Pharmacies (2023-2034) ($MN)
Table 35 Global Neuroimmune Therapy Market Outlook, By Online Pharmacies (2023-2034) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.
Table 1 Global Neuroimmune Therapy Market Outlook, By Region (2023-2034) ($MN)
Table 2 Global Neuroimmune Therapy Market Outlook, By Therapy Type (2023-2034) ($MN)
Table 3 Global Neuroimmune Therapy Market Outlook, By Monoclonal Antibodies (2023-2034) ($MN)
Table 4 Global Neuroimmune Therapy Market Outlook, By Immunomodulators (2023-2034) ($MN)
Table 5 Global Neuroimmune Therapy Market Outlook, By Cytokine Inhibitors (2023-2034) ($MN)
Table 6 Global Neuroimmune Therapy Market Outlook, By Cell-Based Therapies (2023-2034) ($MN)
Table 7 Global Neuroimmune Therapy Market Outlook, By Gene Therapies (2023-2034) ($MN)
Table 8 Global Neuroimmune Therapy Market Outlook, By Small Molecule Drugs (2023-2034) ($MN)
Table 9 Global Neuroimmune Therapy Market Outlook, By Combination Therapies (2023-2034) ($MN)
Table 10 Global Neuroimmune Therapy Market Outlook, By Indication (2023-2034) ($MN)
Table 11 Global Neuroimmune Therapy Market Outlook, By Multiple Sclerosis (2023-2034) ($MN)
Table 12 Global Neuroimmune Therapy Market Outlook, By Neuromyelitis Optica (2023-2034) ($MN)
Table 13 Global Neuroimmune Therapy Market Outlook, By Autoimmune Encephalitis (2023-2034) ($MN)
Table 14 Global Neuroimmune Therapy Market Outlook, By Myasthenia Gravis (2023-2034) ($MN)
Table 15 Global Neuroimmune Therapy Market Outlook, By Alzheimer’s Disease (2023-2034) ($MN)
Table 16 Global Neuroimmune Therapy Market Outlook, By Parkinson’s Disease (2023-2034) ($MN)
Table 17 Global Neuroimmune Therapy Market Outlook, By Route of Administration (2023-2034) ($MN)
Table 18 Global Neuroimmune Therapy Market Outlook, By Intravenous (2023-2034) ($MN)
Table 19 Global Neuroimmune Therapy Market Outlook, By Subcutaneous (2023-2034) ($MN)
Table 20 Global Neuroimmune Therapy Market Outlook, By Oral (2023-2034) ($MN)
Table 21 Global Neuroimmune Therapy Market Outlook, By Intrathecal (2023-2034) ($MN)
Table 22 Global Neuroimmune Therapy Market Outlook, By Technology (2023-2034) ($MN)
Table 23 Global Neuroimmune Therapy Market Outlook, By Biologics Development (2023-2034) ($MN)
Table 24 Global Neuroimmune Therapy Market Outlook, By Recombinant DNA Technology (2023-2034) ($MN)
Table 25 Global Neuroimmune Therapy Market Outlook, By Cell Engineering (2023-2034) ($MN)
Table 26 Global Neuroimmune Therapy Market Outlook, By Precision Medicine Platforms (2023-2034) ($MN)
Table 27 Global Neuroimmune Therapy Market Outlook, By End User (2023-2034) ($MN)
Table 28 Global Neuroimmune Therapy Market Outlook, By Hospitals (2023-2034) ($MN)
Table 29 Global Neuroimmune Therapy Market Outlook, By Specialty Clinics (2023-2034) ($MN)
Table 30 Global Neuroimmune Therapy Market Outlook, By Research Institutes (2023-2034) ($MN)
Table 31 Global Neuroimmune Therapy Market Outlook, By Ambulatory Surgical Centers (2023-2034) ($MN)
Table 32 Global Neuroimmune Therapy Market Outlook, By Distribution Channel (2023-2034) ($MN)
Table 33 Global Neuroimmune Therapy Market Outlook, By Hospital Pharmacies (2023-2034) ($MN)
Table 34 Global Neuroimmune Therapy Market Outlook, By Retail Pharmacies (2023-2034) ($MN)
Table 35 Global Neuroimmune Therapy Market Outlook, By Online Pharmacies (2023-2034) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.
